Supplementation of Magnolol Attenuates Skeletal Muscle Atrophy in Bladder Cancer-Bearing Mice Undergoing Chemotherapy via Suppression of FoxO3 Activation and Induction of IGF-1
Open accessAbstract
Skeletal muscle atrophy, the most prominent phenotypic feature of cancer cachexia, is often observed in cancer patients undergoing chemotherapy. Magnolol (M) extracted from Magnolia officinalis exhibits several pharmacological effects including anti-inflammatory and anticancer activities. In this study, we investigated whether magnolol supplementation protects against the development of cachexia symptoms in bladder cancer-bearing mice undergoing chemotherapy. Combined treatment of magnolol with chemotherapeutic drugs, such as gemcitabine and cisplatin (TGCM) or gemcitabine (TGM), markedly attenuates the body weight loss and skeletal muscle atrophy compared with conventional chemotherapy (TGC). The antiatrophic effect of magnolol may be associated with inhibition of myostatin and activin A formation, as well as FoxO3 transcriptional activity resulting from Akt activation, thereby suppressing ubiquitin ligases MuRF-1 and MAFbx/atrogin-1 expression, as well as proteasomal enzyme activity. Notably, magnolol-induced insulin-like growth factor 1 (IGF-1) production and related protein synthesis may also contribute to its protective effects. The decreased food intake, and intestinal injury and dysfunction observed in the mice of TGC group were significantly improved in the TGCM and TGM groups. Moreover, the increased inflammatory responses evidenced by elevation of proinflammatory cytokine formation and NF-κB activation occurred in the atrophying muscle of TGC group were markedly inhibited in mice of combined treatment with magnolol. In summary, these findings support that magnolol is a promising chemopreventive supplement for preventing chemotherapy-induced skeletal muscle atrophy associated with cancer cachexia by suppressing muscle protein degradation, and inflammatory responses, as well as increasing IGF-1-mediated protein synthesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Magnolol attenuates skeletal muscle atrophy in bladder cancer-bearing BALB/c mice undergoing chemotherapy via suppression of FoxO3a and induction of IGF-1 and subsequent downregulation of MuRF-1 and MAFbx.
“Magnolol attenuates skeletal muscle atrophy in bladder cancer-bearing BALB/c mice undergoing chemotherapy via suppression of FoxO3a and induction of IGF-1 and subsequent downregulation of MuRF-1 and MAFbx [100].”
From Nutraceuticals in the Prevention and Treatment of the Muscle Atrophy (2021) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Definition and classification of cancer cachexia: an international consensus
Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I. G., Bruera, E. D., Fainsinger, R. L., Jatoi, A., Loprinzi, C. L., Macdonald, N., Mantovani, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70218-7 · Cited by 5,800 · see citing works
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · see citing works
Stitt, T. N., Drujan, D., Clarke, B. A., Panaro, F., Timofeyva, Y., Kline, W. O., Gonzalez, M., Yancopoulos, G. D., & Glass, D. J. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00211-4 · Cited by 1,964 · see citing works
FoxO3 Controls Autophagy in Skeletal Muscle In Vivo
Mammucari, C., Milan, G., Romanello, V., Masiero, E., Rudolf, R., Del Piccolo, P., Burden, S. J., Di Lisi, R., Sandri, C., Zhao, J., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.001 · Cited by 1,953 · see citing works
Rommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · see citing works
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression
Lecker, S. H., Jagoe, R. T., Gilbert, A., Gomes, M., Baracos, V., Bailey, J., Price, S. R., Mitch, W. E., & Goldberg, A. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-0610com · Cited by 1,539 · see citing works
Musarò, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., L Sweeney, H., & Rosenthal, N. (2001) · Nature Genetics · doi:10.1038/84839 · Cited by 1,137 · see citing works
Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation
Thomas, M., Langley, B., Berry, C., Sharma, M., Kirk, S., Bass, J., & Kambadur, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004356200 · Cited by 1,014 · see citing works
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T. C., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 941 · see citing works
Signaling in Muscle Atrophy and Hypertrophy
Sandri, M. (2008) · Physiology · doi:10.1152/physiol.00041.2007 · Cited by 830 · see citing works
FoxO transcription factors; Regulation by AKT and 14-3-3 proteins
Tzivion, G., Dobson, M., & Ramakrishnan, G. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.06.002 · Cited by 728 · see citing works
Carter, M. E., & Brunet, A. (2007) · Current Biology · doi:10.1016/j.cub.2007.01.008 · Cited by 581 · see citing works
Inhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J. D., Davies, M. V., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P. E., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503 · see citing works
Therapeutic applications of compounds in the Magnolia family
Lee, Y., Lee, Y. M., Lee, C., Jung, J., Han, S., & Hong, J. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.010 · Cited by 490 · see citing works
Self-citationRegulation of muscle mass by growth hormone and IGF‐I
Velloso, C. P. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.153 · Cited by 444 · see citing works
The role of myostatin in muscle wasting: an overview
Elkina, Y., von Haehling, S., Anker, S. D., & Springer, J. (2011) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1007/s13539-011-0035-5 · Cited by 349 · see citing works
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · see citing works
Cancer Cachexia: Mechanisms and Clinical Implications
Donohoe, C. L., Ryan, A. M., & Reynolds, J. V. (2011) · Gastroenterology Research and Practice · doi:10.1155/2011/601434 · Cited by 273 · see citing works
Role of interleukin-6 in cachexia
Narsale, A. A., & Carson, J. A. (2014) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000091 · Cited by 205 · see citing works
Effect of Branched-Chain Amino Acids on Muscle Atrophy in Cancer Cachexia
Eley, H. L., Russell, S. T., & Tisdale, M. J. (2007) · Biochemical Journal · doi:10.1042/bj20070651 · Cited by 184 · see citing works
Muscle myostatin signalling is enhanced in experimental cancer cachexia
Costelli, P., Muscaritoli, M., Bonetto, A., Penna, F., Reffo, P., Bossola, M., Bonelli, G., Doglietto, G. B., Baccino, F. M., & Fanelli, F. R. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.01970.x · Cited by 181 · see citing works
Inflammation Based Regulation of Cancer Cachexia
Onesti, J. K., & D, D. C. G. (2014) · BioMed Research International · doi:10.1155/2014/168407 · Cited by 157 · see citing works
Soares, P. M. G., Mota, J. M., Gomes, A. S., de Oliveira, R. B., Assreuy, A. M. S., Brito, G. A. D. C., dos Santos, A. A., Ribeiro, R. A., & de Souza, M. H. L. P. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0715-9 · Cited by 146 · see citing works
The pivotal role of cytokines in muscle wasting during cancer
Argilés, J. M. A., Busquets, S., & López-Soriano, F. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.03.014 · Cited by 142 · see citing works
Braun, T. P., Szumowski, M., Levasseur, P. R., Grossberg, A. J., Zhu, X., Agarwal, A., & Marks, D. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106489 · Cited by 93 · see citing works
Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks
Wing, S. S., Lecker, S. H., & Jagoe, R. T. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.586171 · Cited by 90 · see citing works
Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients
Aversa, Z., Bonetto, A., Penna, F., Costelli, P., Rienzo, G. D., Lacitignola, A., Baccino, F. M., Ziparo, V., Mercantini, P., Fanelli, F. R., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1720-5 · Cited by 83 · see citing works
Chen, M., Lee, C.-F., Huang, W., & Chou, T. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.009 · Cited by 80 · see citing works
Self-citationChemotherapy: managing side effects and safe handling.
MacDonald, V. S. (2009) · PubMed · Cited by 77 · see citing works
Zheng, Z., Zhou, L., Gao, S., Yang, Z., Yao, J., & Zheng, S. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6050 · Cited by 76 · see citing works
Fanzani, A., Zanola, A., Rovetta, F., Rossi, S., & Aleo, M. F. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.11.003 · Cited by 72 · see citing works
Chemotherapy: managing side effects and safe handling.
Macdonald (2009) · The Canadian veterinary journal = La revue veterinaire canadienne · Cited by 66 · see citing works
Lazarus, D. D., Moldawer, L. L., & Lowry, S. F. (1993) · PubMed · Cited by 62 · see citing works
Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients
Rhoads, M. G., Kandarian, S. C., Pacelli, F., Doglietto, G. B., & Bossola, M. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.008 · Cited by 58 · see citing works
Ubiquitin ligases MuRF1 and MAFbx in human skeletal muscle atrophy
de Palma, L., Marinelli, M., Pavan, M., & Orazi, A. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.04.019 · Cited by 57 · see citing works
Proteasomal activity in skeletal muscle: A matter of assay design, muscle type, and age
Strucksberg, K.-H., Tangavelou, K., Schröder, R., & Clemen, C. S. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.12.026 · Cited by 53 · see citing works
Changes in the Mucus Barrier during Cisplatin-Induced Intestinal Mucositis in Rats
Yamamoto, H., Ishihara, K., Takeda, Y., Koizumi, W., & Ichikawa, T. (2013) · BioMed Research International · doi:10.1155/2013/276186 · Cited by 48 · see citing works
Ge, X., Zhang, Y., & Jiang, H. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.017 · Cited by 43 · see citing works
Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure
Ebner, N., Elsner, S., Springer, J., & von Haehling, S. (2014) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000030 · Cited by 33 · see citing works
Gemcitabine and Cisplatin for Advanced, Metastatic Bladder Cancer
Cohen, M. H., Rothmann, M. D., von der Maase, H., & Hayden, A. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1229 · Cited by 29 · see citing works
Yü, D., Lee, C.-F., & Chang, S. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.09.074 · Cited by 16 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The role of exercise-induced myokines in regulating metabolism
Huh, J. Y. (2018) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0994-y · Cited by 242 · see citing works
Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer
Ranaware, A. M., Banik, K., Deshpande, V., Padmavathi, G., Roy, N. K., Sethi, G., Fan, L., Kumar, A. P., & Kunnumakkara, A. B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082362 · Cited by 170 · see citing works
Zhuang, J., Shen, L., Yang, L., Huang, X., Lu, Q., Cui, Y., Zheng, X. E., Zhao, X., Zhang, D., Huang, R., et al. (2017) · Theranostics · doi:10.7150/thno.19542 · Cited by 144 · see citing works
Polyphenols and Their Effects on Muscle Atrophy and Muscle Health
Nikawa, T., Ulla, A., & Sakakibara, I. (2021) · Molecules · doi:10.3390/molecules26164887 · Cited by 140 · see citing works
Forkhead Box O Signaling Pathway in Skeletal Muscle Atrophy
Chen, K., Gao, P., Li, Z., Dai, A., Yang, M. W. O., Chen, S., Su, J., Deng, Z., & Li, L. (2022) · American Journal Of Pathology · doi:10.1016/j.ajpath.2022.09.003 · Cited by 122 · see citing works
Insights on the Multifunctional Activities of Magnolol
Zhang, J., Chen, Z., Huang, X., Shi, W., Zhang, R., Chen, M., Huang, H., & Wu, L. (2019) · BioMed Research International · doi:10.1155/2019/1847130 · Cited by 109 · see citing works
Self-citationWu, C.-H., Ko, J., Liao, J., Huang, S., Lin, M., Lee, L.-H., Chang, L.-Y., & Ou, C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918821021 · Cited by 106 · see citing works
Polyphenols and Their Potential Role in Preventing Skeletal Muscle Atrophy
Salucci, S., & Falcieri, E. (2020) · Nutrition Research · doi:10.1016/j.nutres.2019.11.004 · Cited by 83 · see citing works
Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere
Campelj, D. G., Goodman, C. A., & Rybalka, E. (2021) · Cancers · doi:10.3390/cancers13143615 · Cited by 67 · see citing works
Animal models for cancer cachexia
Ballarò, R., Costelli, P., & Penna, F. (2016) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000233 · Cited by 63 · see citing works
Moreira‐Pais, A., Ferreira, R. M., & da Costa, R. M. G. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.07.010 · Cited by 63 · see citing works
Nutraceuticals in the Prevention and Treatment of the Muscle Atrophy
Wang, Y., Liu, Q., Quan, H., Kang, S.-G., Huang, K., & Tong, T. (2021) · Nutrients · doi:10.3390/nu13061914 · Cited by 61 · see citing works
Brierley, D. I., Harman, J. R., Giallourou, N., Leishman, E., Roashan, A. E., Mellows, B., Bradshaw, H. B., Swann, J. R., Patel, K., Whalley, B. J., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12426 · Cited by 50 · see citing works
Lin, M., Ko, J., Liu, T.-C., Chao, P.-T., & Ou, C. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735417753543 · Cited by 50 · see citing works
Synthesis of magnolol and honokiol derivatives and their effect against hepatocarcinoma cells
Maioli, M., Basoli, V., Carta, P., Fabbri, D., Dettori, M. A., Cruciani, S., Serra, P. A., & Delogu, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192178 · Cited by 45 · see citing works
Natural compounds modulating mitophagy: Implications for cancer therapy
Cao, M., Tang, Y., Luo, Y., Gu, F., Zhu, Y., Liu, X., Yan, C., Hu, W., Wang, S., Chao, X., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216590 · Cited by 44 · see citing works
Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation
Lee, C., Jeong, H., Lee, H., Hong, M., Park, S.-Y., & Bae, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00077 · Cited by 34 · see citing works
Self-citationPathophysiological changes of muscle after ischemic stroke: a secondary consequence of stroke injury
Hu, Q., Tian, D., Luan, F., Yang, R., & Zeng, N. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382221 · Cited by 33 · see citing works
Keshta, A. T., Fathallah, A. M., Attia, Y. A., Salem, E. A., & Watad, S. H. (2023) · Food and Chemical Toxicology · doi:10.1016/j.fct.2023.113979 · Cited by 28 · see citing works
Zhou, S., Wen, H., & Li, H. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28968 · Cited by 28 · see citing works
miR-628 Promotes Burn-Induced Skeletal Muscle Atrophy via Targeting IRS1
Yu, Y., Li, X., Liu, L., Chai, J., Haijun, Z., Chu, W., Yin, H., Ma, L., Duan, H., & Xiao, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15496 · Cited by 27 · see citing works
Zhang, H., Ju, B., Zhang, X., Zhu, Y., Nie, Y., Xu, Y., & Lei, Q. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12749 · Cited by 23 · see citing works
Huang, K., Chiang, Y., Ali, M. R., & Hsia, S. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13817 · Cited by 22 · see citing works
Promising models for cancer-induced cachexia drug discovery
Suzuki, T., von Haehling, S., & Springer, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1724954 · Cited by 22 · see citing works
Miyata, Y., Matsuo, T., Ohba, K., Mitsunari, K., Mukae, Y., Otsubo, A., Harada, J., Matsuda, T., Kondo, T., & Sakai, H. (2020) · Cancers · doi:10.3390/cancers12123776 · Cited by 20 · see citing works
Hong, M., Han, I., Choi, I., Cha, N., Kim, W., Kim, S. K., & Bae, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063188 · Cited by 20 · see citing works
Yang, J., Cao, R. Y., Li, Q. X., & Zhu, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_15 · Cited by 16 · see citing works
Role for Plant-Derived Antioxidants in Attenuating Cancer Cachexia
Li, W., Swiderski, K., Murphy, K. T., & Lynch, G. S. (2022) · Antioxidants · doi:10.3390/antiox11020183 · Cited by 16 · see citing works
Lee, C., Kang, M. J., Kim, S., Han, I., & Bae, H. (2021) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00181-2 · Cited by 8 · see citing works
Self-citationFontana, R., Mattioli, L., Biotti, G., Budriesi, R., Gotti, R., Micucci, M., Corazza, I., Marconi, P., Frosini, M., Manfredini, S., et al. (2023) · Phytotherapy Research · doi:10.1002/ptr.7786 · Cited by 8 · see citing works
Cachexia and bladder cancer: clinical impact and management.
Lokeshwar, S. D., Press, B. H., Nie, J., Klaassen, Z. W. A., Kenney, P. A., & Leapman, M. (2021) · PubMed · doi:10.1097/spc.0000000000000580 · Cited by 5 · see citing works
da Silva, F. M., Lim, S., Cabrera, A. R., Chambers, T. L., Koopmans, P. J., Tsitkanou, S., Khadgi, S., Peterson, C. S., Schrems, E. R., Muhyudin, R., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14630-x · Cited by 5 · see citing works
An analysis of the types of recently published research in the field of cachexia
Shewan, L. G. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317730943 · Cited by 5 · see citing works
Rayamajhi, A., Gyawali, N., Karki, D., Pérez‐Caltzontzin, L. E., Peña‐Corona, S. I., Cortés, H., Adhikari, A., Leyva‐Gómez, G., Uprety, Y., Habtemariam, S., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02409-2 · Cited by 4 · see citing works
Xia, Y., Gao, X., Niu, Q., Peng, X., Zhang, J., Ma, X., Wei, Y., Wang, H., Gao, Y., & Chang, H. (2021) · Experimental Physiology · doi:10.1113/ep089187 · Cited by 3 · see citing works
Tinivella, A., Nwachukwu, J. C., Pinzi, L., Dettori, M. A., Fabbri, D., Carta, P., Nettles, K. W., & Rastelli, G. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00634 · Cited by 3 · see citing works
Fakhri, S., Piri, S., & Khan, H. Z. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824356-5.00007-2 · Cited by 2 · see citing works
Li, X., Jing, Z., Zhao, W.-R., Tang, J.-Y., & Zhou, Z.-Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189598 · Cited by 1 · see citing works
Protective Effects of Ligandrol Against Cisplatin-Induced Mouse Muscle Cell Line Toxicity
Ustun, Z., Akkan, T., & Güner, A. (2025) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-025-03337-9 · Cited by 1 · see citing works
Effect of exercise on neuromuscular toxicity in oxaliplatin‐treated mice
Lees, J. G., Abdulla, M., Barkl‐Luke, M. E., Livni, L., Keating, B. A., Hayes, J. P., Fiore, N. T., Park, S. B., Moalem‐Taylor, G., & Goldstein, D. (2021) · Muscle & Nerve · doi:10.1002/mus.27329 · Cited by 1 · see citing works
Sakaue, M., Yamamoto, A., Onishi, T., Oyabu, M., & Kamei, Y. (2026) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbag033
Huang, Z., Huang, Z., Luo, L., Wu, Z., Wen, Z., & Zhihua, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1971993
- Authors
- Chen, M.-C., Chen, Y.-L., Lee, C.-F., Hung, C.-H., & Chou, T.-C.
- Affiliations
- National Defense Medical Center (TW)
- Fu Jen Catholic University (TW)
- Tzu Chi University (TW)
- Asia University (TW)
- Corresponding author
- Chou, Tz-Chong
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-11-24
- Volume
- 10
- Issue
- 11
- Pages
- e0143594
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4657971
- OpenAlex
- W2178033743
- Cited by
- 45
- References
- 41
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 5 · 2017: 3 · 2016: 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
- Health Sciences › Medicine › Rehabilitation › Magnolia and Illicium research
- Keywords
- magnolol, skeletal muscle atrophy, cancer cachexia, bladder cancer, FOXO3, insulin-like growth factor I, myostatin, activin A, MuRF1, atrogin-1, ubiquitin ligase, proteasome, NF-κB, inflammatory cytokines, gemcitabine, cisplatin, Magnolia officinalis, chemoprevention, intestinal dysfunction
- MeSH terms
- Forkhead Box Protein O3, Animals, Biphenyl Compounds, Urinary Bladder Neoplasms, Body Weight, Insulin-Like Growth Factor I, Male, Mice, Nude, Muscular Atrophy, Tumor Necrosis Factor-alpha, Interleukin-6, NF-kappa B, Lignans, Proteasome Endopeptidase Complex, Mice, Forkhead Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
